Bart Barlogie Young Investigator Award for Clinical/Therapeutics

In recognition to the outstanding research developed by Dr. Bart Barlogie in the field of multiple myeloma, the IMS Board of Directors established the Bart Barlogie Young Investigator Award. This award is aimed at formally recognizing and stimulating excellence in myeloma research.

The Young Investigator Award will be given to an investigator 45 years of age or younger in recognition of their research in the myeloma field. An award of US $25,000 is given by the IMS this International Myeloma Workshops.

Award Amount

The awardee will receive $25,000 which can only be used to support the awardee’s myeloma research.

Award Terms
  • If selected for an award, the recipient will agree to cite support from the International Myeloma Society (IMS) in any publication resulting from the research conducted during the award period.
  • Research award funds cannot be deferred and are non-transferable.
  • This award gift does not allow for any indirect costs.
Award Reports

A summary of the research conducted within the two years following the Award must be submitted as a progress report to the IMS Board.


If you have any questions or require additional information regarding the Bart Barlogie Young Investigator Award, please contact

Past Winner Profile

Dr. Palladini has been involved in research in the field of AL amyloidosis since 1994, when he joined the Pavia group led by Dr. Giampaolo Merlini. He earned his MD degree in 1997 and his PhD degree in 2007. He worked as a consultant at the Pavia Amyloidosis Research Center since 2005 and in 2016 he was appointed the Deputy (Head) of the Center. He his Associate Professor of Clinical Chemistry at the University of Pavia.

Dr. Palladini’s research focuses on the diagnosis, prognostic stratification, and treatment of AL amyloidosis. In particular, he explored biomarkers of clonal disease and organ involvement as hints to early diagnosis, prognostic indicators, and markers of response. These studies led to the introduction of N-terminal pro-natriuretic peptide type-B (NT-proBNP) in the management of AL amyloidosis, to the establishment of a staging system for renal involvement, and to the definition of the current criteria for hematologic, cardiac, and renal response in AL amyloidosis.

Dr. Palladini designed and performed or coordinated several clinical trials in AL amyloidosis, introducing oral melphalan and dexamethasone (MDex) as a standard of care for transplant ineligible patients and assessing the safety and efficacy of new drugs in this disease. More recently, he coordinated the first completed international phase III study of novel agents in this disease, comparing MDex with bortezomib plus MDex.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide. The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events